Document is current
Any future updates will be listed below
-
Authors
Wu, Y. Linda
Cappuyns, Sarah
Loh, Amanda
Sun, Sean
Lewis, Sara
Sung, Max W.
Schwartz, Myron
Llovet, Josep M.
Cohen, Deirdre J.
- License Information
-
More Information
Article History
Received: 5 October 2023
Revised: 28 November 2023
Accepted: 8 January 2024
First Online: 29 January 2024
Competing interests
: MWS received consulting fees from Bayer, EISAI, and Exelixis. JML received research support from Bayer HealthCare Pharmaceuticals, Eisai Inc., Bristol Myers Squibb, Boehringer-Ingelheim and Ipsen and consulting fees from Merck, Eli Lilly, Eisai Inc., Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Exelixis, Ipsen, Genentech, Roche, Glycotest, Nucleix, Mina Alpha Ltd. and AstraZeneca. All other authors have no financial conflicts of interest to disclose.
: The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice standards. Ethical approval to conduct this study was reviewed by the Institutional Review Board (IRB) at Icahn School of Medicine at Mount Sinai (Reference #21–00945). According to standard guidelines, patient consent was waived by the IRB given the retrospective and anonymized nature of this study.
